CDC Recommends the Updated COVID-19 Booster (Omicron/Bivalent booster) September 1, 2022

CDC now recommends that all persons ages 12 years and older receive an updated (also called “bivalent”) booster to improve protection against serious COVID-19 disease. The updated COVID-19 boosters were formulated to better protect against the COVID-19 Omicron BA.4/BA.5 strains, in addition to the original COVID-19 strain. CDC anticipates that most people will need a once-yearly booster based on changes in COVID-19 strains.

Who should get an updated booster?
- Everyone 12 years and older who has completed the primary COVID-19 vaccine series should get the updated booster. This includes persons who have already received a prior booster.

When should I get an updated booster?
- Persons must complete their primary COVID-19 vaccine series and then wait at least 2 months after their most recent dose of any COVID-19 vaccine before getting an updated booster. You can get your updated booster at the same time as other vaccines, including flu vaccine.

What updated booster products are available?
- The updated Pfizer booster is authorized for children ages 12-17 years and adults ages 18 years and older.
- The updated Moderna booster is authorized for adults ages 18 years and older.

Do young children need COVID-19 vaccine boosters?
- Children ages 6 months-4 years should receive the COVID-19 primary series.
- Children ages 5-11 years continue to be eligible for the original booster.
- CDC will provide information about updated boosters for children in the near future.

Where can I get my updated COVID-19 boosters?
- TONHC will offer the updated booster COVID-19 vaccines at TONHC clinics and community events beginning in late September 2022. We will announce locations, dates and times. Be sure to bring your COVID-19 vaccination card(s) with you.
- You can also check [www.vaccines.gov](http://www.vaccines.gov) for pharmacies and other vaccination sites that offer COVID-19 vaccines.
- Use the CDC’s website tool to: “Find Out When to Get a Booster”.

Stay up-to-date with your COVID-19 and other vaccinations. Vaccinations help to protect you, your loved ones, and your community.
**COVID-19 Vaccination Schedule for Most People**

(People who are NOT Moderately or Severely Immunocompromised)

### People ages 6 months through 4 years

<table>
<thead>
<tr>
<th>Schedule</th>
<th>Age Group</th>
<th>Vaccine</th>
<th>Timeframe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary</td>
<td>6-23 months</td>
<td>Pfizer-BioNTech</td>
<td>In 3-8 weeks</td>
</tr>
<tr>
<td>Primary</td>
<td>6-23 months</td>
<td>Pfizer-BioNTech</td>
<td>In at least 8 weeks</td>
</tr>
</tbody>
</table>

-OR-

<table>
<thead>
<tr>
<th>Schedule</th>
<th>Age Group</th>
<th>Vaccine</th>
<th>Timeframe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary</td>
<td>24 months-4 years</td>
<td>Moderna, Novavax, or Pfizer-BioNTech</td>
<td>In 3-8 weeks (Novavax, Pfizer) or in 4-8 weeks (Moderna)</td>
</tr>
<tr>
<td>Primary</td>
<td>24 months-4 years</td>
<td>Bivalent booster*</td>
<td>In at least 2 months</td>
</tr>
</tbody>
</table>

### People ages 5 through 11 years

<table>
<thead>
<tr>
<th>Schedule</th>
<th>Age Group</th>
<th>Vaccine</th>
<th>Timeframe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary</td>
<td>5-11 years</td>
<td>Moderna</td>
<td>In 4-8 weeks</td>
</tr>
<tr>
<td>Primary</td>
<td>5-11 years</td>
<td>Pfizer-BioNTech</td>
<td>In at least 5 months</td>
</tr>
</tbody>
</table>

### People ages 12 years and older

<table>
<thead>
<tr>
<th>Schedule</th>
<th>Age Group</th>
<th>Vaccine</th>
<th>Timeframe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary</td>
<td>12 years and older</td>
<td>Moderna, Novavax, or Pfizer-BioNTech</td>
<td>In 3-8 weeks (Novavax, Pfizer) or in 4-8 weeks (Moderna)</td>
</tr>
<tr>
<td>Primary</td>
<td>12 years and older</td>
<td>Bivalent booster*</td>
<td>In at least 2 months</td>
</tr>
</tbody>
</table>

### People ages 18 years and older who previously received Janssen primary series dose†

<table>
<thead>
<tr>
<th>Schedule</th>
<th>Age Group</th>
<th>Vaccine</th>
<th>Timeframe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary</td>
<td>18 years and older</td>
<td>Bivalent booster*</td>
<td>In at least 2 months</td>
</tr>
</tbody>
</table>

---

*Note:* This schedule does not include clinical details necessary for administering COVID-19 vaccines. For clinical details, see the resources at the end of this document.

* The bivalent booster dose is administered at least 2 months after completion of the primary series. For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose.

† Janssen COVID-19 Vaccine should only be used in certain limited situations. See: [https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a)

For more specific clinical guidance, see:
- [Pre-exposure prophylaxis](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a)
- [Interim COVID-19 Immunization Schedule](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a)
- [Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a)
COVID-19 Vaccination Schedule for People Who Are Moderately or Severely Immunocompromised

People ages 6 months through 4 years

**Moderna**
- Primary → Primary
- In 4 weeks
- In at least 4 weeks

**Pfizer-BioNTech**
- Primary → Primary
- In at least 4 weeks

-OR-

**Moderna**
- Primary → Primary
- In 4 weeks
- In at least 4 weeks

**Pfizer-BioNTech**
- Primary → Primary
- In at least 4 weeks

People ages 5 years through 11 years

**Moderna**
- Primary → Primary
- In 4 weeks
- In at least 4 weeks

**Pfizer-BioNTech**
- Primary → Primary
- In 3 weeks
- In at least 4 weeks

-OR-

**Moderna**
- Primary → Primary
- In at least 4 weeks

**Pfizer-BioNTech**
- Primary → Primary
- In at least 4 weeks
- In at least 3 months

**Monovalent Booster**

For more specific clinical guidance, see:
- Pre-exposure prophylaxis
- Interim COVID-19 Immunization Schedule
- Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States
At-a-Glance COVID-19 Vaccination Schedule for People Who Are Moderately or Severely Immunocompromised

People ages 12 years and older

Moderna or Pfizer-BioNTech

Primary

- In 3-8 weeks (Pfizer) or in 4 weeks (Moderna)

Primary

- In at least 4 weeks

Primary

- In at least 2 months

Bivalent booster*

Novavax

Primary

- In 3 weeks

Primary

- In at least 2 months

Bivalent booster*

People ages 18 years and older who previously received Janssen primary series dose†

Primary

- In at least 4 weeks

Addl mRNA dose

- In at least 2 months

Bivalent booster*

Monoclonal antibodies (EVUSHELD™) for COVID-19 pre-exposure prophylaxis

People ages 12 years and older (must weigh at least 40kg)

Any dose (primary or booster)

- In at least 2 weeks

EVUSHELD™ dose every 6 months

No minimum interval from EVUSHELD™ to COVID-19 vaccine

Any subsequent COVID-19 vaccine dose

- At least 2 weeks from COVID-19 vaccine to EVUSHELD™

For more specific clinical guidance, see:

- Pre-exposure prophylaxis
- Interim COVID-19 Immunization Schedule
- Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States

Note: This schedule does not include clinical details necessary for administering COVID-19 vaccines. For clinical details, see the resources at the end of this document.

* The bivalent booster dose is administered at least 2 months after completion of the primary series. For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose.

† Janssen COVID-19 Vaccine should only be used in certain limited situations. See: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a